Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3491-3500 Newer>

The Motley Fool February 22, 2007 Tom Taulli	HealthStream Is More Like a Puddle A major technology transition is slowing the growth at this e-learning software developer for the health-care sector. Investors, take note.
The Motley Fool February 21, 2007 Billy Fisher	Scorching Sales Growth at ev3 Profits should be arriving soon for this medical device maker. The medical breakthroughs already are. Investors, take note.
The Motley Fool February 21, 2007 Brian Lawler	Gilead Closes the Gap The FDA trims Gilead's review period for a top developmental compound. Investors, take note.
BusinessWeek February 26, 2007 Arlene Weintraub	The Power Of The Pipeline Bristol-Myers Squibb is beset with troubles, but its new-drug potential makes it a target.
BusinessWeek February 26, 2007 Arlene Weintraub	Pushing The Pills A Bit Too Hard Feds and states are putting drug marketing under the microscope and seeing abuse.
Chemistry World February 15, 2007 Victoria Gill	Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec.
The Motley Fool February 15, 2007 Brian Lawler	A Momenta's Pause The pharmaceutical elaborates on plans for its generic version of blockbuster Lovenox. With so much going on, the rest of 2007 is sure to be a wild ride for Momenta investors.
Pharmaceutical Executive February 1, 2007 Bradley Thompson	Virus as Viable Drug Coincidence or phenomena? The reovirus is Mother Nature's own cancer-killer.
Pharmaceutical Executive February 1, 2007 Bill Chekan	Ain't Misbehavin' Missing doses and other medication meddling are often no accident. A new study of patient compliance uncovers methods to the madness.
Pharmaceutical Executive February 1, 2007 Ben Bonifant et al.	Driven to License The competition for innovative biotech products is intense, giving rise to an unprecedented diversity of partnering strategies and an equally unprecedented convergence of small-molecule drugs and biologics in company portfolios. Licensings are shaping up as the year's big deal.
<Older 3491-3500 Newer> Return to current articles.